Andrea Benediktsdottir
PhD student at Institutionen för läkemedelskemi; Läkemedelsdesign och läkemedelsutveckling
- E-mail:
- andrea.benediktsdottir@ilk.uu.se
- Visiting address:
- Biomedicinskt Centrum BMC, Husargatan 3
- Postal address:
- Box 574
751 23 UPPSALA
More information is available to staff who log in.
Keywords
- antibacterial inhibitors
- drug design and discovery
- macrocyclic lipopeptides
- peptidomimetics
- protease inhibitors
- sulfonimidamides
Research
Since November 2017, I am a PhD student in the Drug Design and Discovery group under the supervision of Anja Sandström. My main research interest lies in discovering new antibacterial agents. I am currently working on design and synthesis of novel inhibitors targeting type I signal peptidase in Gram-negative bacteria for the development of new antibacterial agents.
Publications
Recent publications
- Bacterial type I signal peptidase inhibitors-Optimized hits from nature (2022)
- Antibacterial sulfonimidamide-based oligopeptides as type I signal peptidase inhibitors (2021)
- Influence of Detergent and Lipid Composition on Reconstituted Membrane Proteins for Structural Studies (2021)
- Solid Phase Synthesis of Sulfonimidamide Pseudopeptides and Library Generation (2020)
- Synthesis of Sulfonimidamide-Based Amino Acid Building Blocks with Orthogonal Protecting Groups (2019)
All publications
Articles
- Bacterial type I signal peptidase inhibitors-Optimized hits from nature (2022)
- Antibacterial sulfonimidamide-based oligopeptides as type I signal peptidase inhibitors (2021)
- Influence of Detergent and Lipid Composition on Reconstituted Membrane Proteins for Structural Studies (2021)
- Solid Phase Synthesis of Sulfonimidamide Pseudopeptides and Library Generation (2020)
- Synthesis of Sulfonimidamide-Based Amino Acid Building Blocks with Orthogonal Protecting Groups (2019)
- Boronic ester-linked macrocyclic lipopeptides as serine protease inhibitors targeting Escherichia coli type I signal peptidase (2018)
- Design, synthesis, and in vitro biological evaluation of meta-sulfonamidobenzamide-based antibacterial LpxH inhibitors
